Juno Therapeutics, Inc. v. Juno Biomedical, Inc.

Filing 40

JUDGMENT. ***Civil Case Terminated.*** Signed by Judge Haywood S. Gilliam, Jr. on 4/27/18. (ndrS, COURT STAFF) (Filed on 4/27/2018)

1
2
3
4

UNITED STATES DISTRICT COURT

5

NORTHERN DISTRICT OF CALIFORNIA

6
7

JUNO THERAPEUTICS, INC.,

Case No. 17-cv-04196-HSG

Plaintiff,
8
v.

JUDGMENT

9
10

JUNO BIOMEDICAL, INC.,
Defendant.

United States District Court
Northern District of California

11
12
13
14

Pursuant to Rule 55(b)(2) of the Federal Rules of Civil Procedure, final default judgment is
entered in Plaintiffs’ favor against Defendant Juno Biomedical, Inc. as follows:

15

A.

Default judgment is entered against Defendant on all causes of action.

16

B.

Defendant, its partners, officers, directors, employees, agents, owners, and

17

representatives and all persons, firms, and corporations in active concert or

18

participation with any of them, are enjoined from:

19

1.

using in any manner “JUNO,” “JUNO BIOMEDICAL,” or any trademark,

20

tread name, or domain name including the term JUNO in connection with

21

any goods or service in the fields of medicine or biotechnology;

22

2.

using in any manner “JUNO THERAPEUTICS,” or any trademark, trade

23

name, or domain name that is confusingly similar to or a colorable imitation

24

of “JUNO THERAPEUTICS,” in connection with goods or service in the

25

fields of medicine or biotechnology;

26

3.

doing any act or thing calculated or likely to cause confusion, mistake or

27

deception in the minds of members of the public as to the source of

28

Defendant’s goods or services, or likely to deceive members of the public

1

into believing th there is so affiliati between Juno Therap
hat
ome
ion
peutics and

2

Defe
endant or any other entit owned or controlled b or associa with
ty
by
ated

3

Defe
endant;

4

4.

othe
erwise compe
eting unfairl with Juno Therapeutic in any ma
ly
cs
anner; and

5

5.

assis
sting, aiding, or abetting any other p
g
person or bus
siness entity in engaging
g

6

in or performing any of the a
r
g
activities ref
ferred to in p
parts (1) thro
ough (4) of

7

this paragraph B.
B

8

C.

a
ons,
nd
ons
rt
pation with
Defendant and all perso firms an corporatio in concer of particip
it, as identif in Parag
fied
graph B abov are direct to file wi this Cour and serve
ve,
ted
ith
rt

10

upon Juno Therapeutics within thirt (30) days after entry o the injunction a report
T
s
ty
of
t

11
United States District Court
Northern District of California

9

in writing under oath se
etting forth in detail the m
n
manner and form in whic
ch

12

Defendant has complied with the inj
h
d
njunction and ceased all o
d
offering or p
promoting of
f

13

goods or ser
rvices in the fields of me
edicine and b
biotechnolog under the “JUNO”
gy
e

14

and “JUNO BIOMEDIC
CAL” tradem
mark, trade n
name, and do
omain name as set forth
e

15

above.

16
17
18
19
20
21

6.

The Court awards Plain $56,501 .20 in reason
a
ntiff
nable attorne fees and costs on
eys’
d

the Lanham Ac claims.
e
ct
IT IS SO ORDER
S
RED.
Da
ated: April 27, 2018
2
__________
___________
__________
________
___
Ha
aywood S. G
Gilliam, Jr.
Un
nited States D
District Judg
ge

22
23
24
25
26
27
28
2